Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Resistance is futile?

Debating the inevitability of transparency

The ethics and practicality of data collection and sharing, whether in clinical trials, doctors' performance or a country's defence programme, is a common issue in these connected times.

What should be shared publicly, and with whom, is often contentious, and pharma is by no means alone when it comes to feeling the pressure to open archives and release data.

There certainly seems no escape from trial transparency. For Bad Pharma author Dr Ben Goldacre the industry is following an “inevitable policy trajectory”, he told PME that after the recent European Parliament Committee vote on amending the Clinical Trial Directive the direction of travel “cannot be held back”.

A slightly more nuanced approach can be found in PME magazine, where UCB's Neir Weir says the debate is driven, on both sides, by people who passionately want to do the right thing.

Certainly, we are all aware of the reasons why there is a need for transparency, but it's also becoming clearer and clearer that the issue is a delicate and complex one.

This blog post first appeared as the Editor's comment in PME July/August 2013

Article by
David Stone

is editor of PME and Communiqué

8th August 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....